Selected from:
http://www.nature.com/cgi-taf/DynaPage.taf?file=/ni/journal/v2/n9/special_full/ni0901-775_r.html&filetype=
Nature Immunology 2, 775 (2001)
GM-CSF key in Multiple Sclerosis
J. Exp. Med. 194, 873–881 (2001)
Understanding how inflammatory lesions
are initiated and perpetuated in the CNS has remained crucial to development
of potential therapeutic agents that may block the demyelinating disease
process in MS.
In the J. Exp. Med., Bernard and
colleagues show the hematopoietic growth factor GM-CSF plays a crucial
role in the effector phase of lymphocyte recruitment to the CNS parenchyma
and maintenance of inflammatory lesions.
Mice deficient for GM-CSF developed
fewer clinical symptoms of experimental autoimmune encephalomyelitis (EAE),
as compared to WT mice, when immunized with myelin oligodendrocyte glycoprotein.
Yet, CD4+ immune responses in these
mice, seen by antibody responses in vivo and Con A-stimulated proliferation
in vitro, were not abrogated.
Importantly, blocking GM-CSF action
in vivo ameliorated the disease process in WT mice, even after onset of
symptoms.
Thus, GM-CSF may pose a potential
target for treatment of MS.
Unfavorable cytotoxic T cells
J. Exp. Med. 194, 669–676 (2001)
Plaques of infiltrating CD4+ and
CD8+ T cells of unknown function and specificity are found in multiple
sclerosis (MS) patients.
Research has focused on CD4+ T cells,
as EAE induction is CD4+ T cell–dependent, MS susceptibility is associated
with MHC class II genes and the TCR sequence motifs found within MS plaques
are similar to myelin-specific peripheral CD4+ T cells.
In the Journal of Experimental Medicine,
Huseby et al. show that myelin-specific CD8+ T cells induce severe CNS
autoimmunity in mice.
The disease induced by these CD8+
T cells exhibited some clinical signs and CNS pathology not seen in classic
EAE mediated by myelin-specific CD4+ T cells. IFN-, but not TNF- or Fas-FasL,
interactions played an important role in CD8+ T cells specific for myelin
protein.
These results now implicate CD8+
myelin-specific CTLs, in addition to CD4+ T cells, as mediators of CNS
autoimmunity.
Mimicry or nonspecific stimuli?
Immunity 15, 137–147 (2001)
The association between viral infections
and induction or exacerbation of autoimmune disease is poorly understood.
In Immunity, Cantor and colleagues
examine the relative roles of molecular mimicry and nonspecific inflammatory
stimuli in the transition from infection to autoimmune disease.
They use a replication-competent
murine herpes virus 1 (HSV-1 KOS) point mutant, which contains a single
amino acid exchange in the putative mimicry epitope, and mice expressing
a TCR transgene specific for the self-peptide mimic.
They show that viral mimicry is critical
for disease induction after low-level viral infection of mice containing
limited numbers of autoreactive T cells, whereas innate immune mechanisms
are sufficient to provoke disease in animals containing expanded numbers
of autoreactive T cells.
Thus, both viral mimicry and nonspecific
innate immune mechanisms have dominant roles in the generation of autoimmunity
under particular conditions.
Deviating TH1 cells
Immunity 15, 15–22 (2001)
DNA vaccines can be used to elicit
immunity or tolerance.
To modulate the immune response to
DNA vaccines, preparations that contain cytokine genes and genes to certain
pathogens have been used in "covaccines."
In Immunity, Steinman and colleagues
show covaccination of mice with a construct encoding IL-4 and residues
139–151 of the self-peptide proteolipid protein, PLP(139–151), protects
against experimental autoimmune encephalomyelitis (EAE) induction by PLP(139–151).
IL-4–dependent STAT6 phosphorylation
induced autoreactive T cells to shift their cytokine profile to TH2. In
addition, DNA covaccination with the genes encoding myelin basic protein
and IL-4 can reverse established EAE.
Thus, this method of protective immunity
using DNA vaccination and local gene delivery could prove beneficial in
the treatment of multiple sclerosis and other autoimmune diseases caused
by TH1 autoreactive cells.
© Nature America, Inc